Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2007

View Archived Issues

BIBW-2992 active in preclinical models and patients with non-small cell lung cancer

Natural products for the treatment of sleep disorders

Motexafin gadolinium studied in refractory lung cancer, patients with brain metastases

Intra-Cellular Therapies outlines portfolio of proprietary compounds for FSD

LigoCyte to develop anti-CD103 therapies with Biogen Idec

Positive results for sanofi pasteur's low-dose H5N1 influenza vaccine

Recent patents disclose novel therapeutic agents for cardiovascular disorders

Discovery of agents for neurological disorders reported in recent patent literature

MKC-1 well tolerated in phase II metastatic breast cancer trial

Knee osteoarthritis pain relief observed with IDEA-033

Preclinical antianginal activity of the sodium channel blocker F-15845

Preclinical characterization of DX-2400, a novel fully human antibody against MMP-14

Preclinical activity and pharmacokinetics of the novel PDE5 inhibitor lodenafil carbonate

Astellas Pharma U.S. submits response to FDA action letter for once-daily FK-506

Alexza to begin first of two phase III trials of AZ-004

FDA recommends LipoNova continue autologous RCC vaccine development program

Allergan to acquire Esprit Pharma and partner with Indevus on Sanctura brand

GlaxoSmithKline submits application for SAD indication for Paxil tablet in Japan

PEGylation and Pulmonary research units created by Nektar

Evotec to acquire Renovis

Patient enrollment completed in phase II trial of Gabapentin GR for menopausal hot flashes

AVI BioPharma receives DoD contract for development of NeuGene antisense drug

DelSite Biotechnologies enters technology evaluation agreement for GelSite polymer

RDEA-806: a novel anti-HIV NNRTI safe and well tolerated in human studies

TMC-125 NDA accepted for priority review in U.S.

Campath approved in U.S. for first-line treatment for B-CLL

Novel antifolates with improved activity against staphylococcal and enterococcal infections

Lilly files for European approval of Alimta as first-line treatment of NSCLC

Wyeth receives EMEA opinions on Torisel and Mylotarg

The EC to authorize Yondelis commercialization for soft tissue carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...